Literature DB >> 20842761

Risk of hyperkalemia associated with selective COX-2 inhibitors.

Hisham Aljadhey1, Wanzhu Tu, Richard A Hansen, Susan Blalock, D Craig Brater, Michael D Murray.   

Abstract

BACKGROUND: Selective cyclooxygenase-2 (COX-2) inhibitors have been linked to cardiac death. The mechanism for this adverse effect appears to be by ischemic insult; however another mechanism could involve hyperkalemia. The objective of this study was to determine the effects of selective COX-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) on serum potassium concentration and the electrocardiogram.
METHODS: A retrospective cohort study was conducted using propensity score matching of patients from an inner-city academic medical center at Indianapolis, Indiana. Two hundred and two patients prescribed selective COX-2 inhibitors were matched to 202 patients prescribed non-selective NSAIDs using propensity scores methods. Outcomes included change in serum potassium concentration from baseline and the risk of an abnormal electrocardiogram.
RESULTS: Compared to patients prescribed non-selective NSAIDs, those prescribed a selective COX-2 inhibitor had a higher risk of serum potassium increase greater than 5 mEq/L (OR, 2.56; 95%CI, 1.03-6.36). However, patients prescribed selective COX-2 inhibitors had no greater risk of electrocardiogram abnormality (OR, 1.16; 95%CI, 0.74-1.82).
CONCLUSIONS: Selective COX-2 inhibitors may have a greater risk of hyperkalemia than non-selective NSAIDs. This study was exploratory with small numbers of patients. Further studies are needed to confirm these results and any association with cardiovascular events.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842761      PMCID: PMC3018679          DOI: 10.1002/pds.2011

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  19 in total

Review 1.  Renal effects of cyclooxygyenase-2-selective inhibitors.

Authors:  D Craig Brater
Journal:  J Pain Symptom Manage       Date:  2002-04       Impact factor: 3.612

2.  Using prescription claims data for drugs available over-the-counter (OTC).

Authors:  Marianne Ulcickas Yood; Ulka B Campbell; Kenneth J Rothman; Susan S Jick; Janet Lang; Karen E Wells; Hershel Jick; Christine C Johnson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-09       Impact factor: 2.890

3.  Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Authors:  S K Swan; D W Rudy; K C Lasseter; C F Ryan; K L Buechel; L J Lambrecht; M B Pinto; S C Dilzer; O Obrda; K J Sundblad; C P Gumbs; D L Ebel; H Quan; P J Larson; J I Schwartz; T A Musliner; B J Gertz; D C Brater; S L Yao
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

4.  Structure, functions, and activities of a research support informatics section.

Authors:  Michael D Murray; Faye E Smith; Joanne Fox; Evgenia Y Teal; Joseph G Kesterson; Troy A Stiffler; Roberta J Ambuehl; Jane Wang; Maria Dibble; Dennis O Benge; Leonard J Betley; William M Tierney; Clement J McDonald
Journal:  J Am Med Inform Assoc       Date:  2003-03-28       Impact factor: 4.497

5.  Hyperkalaemic quadriparesis secondary to chronic diclofenac treatment.

Authors:  P Patel; B Mandal; M W Greenway
Journal:  Postgrad Med J       Date:  2001-01       Impact factor: 2.401

6.  Too much ado about propensity score models? Comparing methods of propensity score matching.

Authors:  Onur Baser
Journal:  Value Health       Date:  2006 Nov-Dec       Impact factor: 5.725

Review 7.  The management of hyperkalemia in patients with cardiovascular disease.

Authors:  Apurv Khanna; William B White
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

8.  Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis.

Authors:  L Niccoli; S Bellino; F Cantini
Journal:  Clin Exp Rheumatol       Date:  2002 Mar-Apr       Impact factor: 4.473

9.  Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet.

Authors:  Emile Hay; Hashmonai Derazon; Natalia Bukish; Leonid Katz; Igor Kruglyakov; Michael Armoni
Journal:  J Emerg Med       Date:  2002-05       Impact factor: 1.484

10.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

View more
  4 in total

1.  Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.

Authors:  Danielle M Nash; Maureen Markle-Reid; Kenneth S Brimble; Eric McArthur; Pavel S Roshanov; Jeffrey C Fink; Matthew A Weir; Amit X Garg
Journal:  Nephrol Dial Transplant       Date:  2019-07-01       Impact factor: 5.992

Review 2.  Drug-induced hyperkalemia.

Authors:  Chaker Ben Salem; Atef Badreddine; Neila Fathallah; Raoudha Slim; Houssem Hmouda
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

3.  The association between nonsteroidal anti-inflammatory drugs and potassium concentrations: A pharmacoepidemiological study in Saudi Arabia.

Authors:  Hisham Aljadhey
Journal:  Saudi Pharm J       Date:  2011-08-23       Impact factor: 4.330

4.  Drug Design, Synthesis and Biological Evaluation of Heterocyclic Molecules as Anti-Inflammatory Agents.

Authors:  Jignasa Savjani; Bhavesh Variya; Snehal Patel; Suja Mulamkattil; Harsh Amin; Shital Butani; Ahmed Allam; Jamaan Ajarem; Harsh Shah
Journal:  Molecules       Date:  2022-02-14       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.